Found 98 Vision Loss trials
A listing of Vision Loss medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Evaluating BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF)
This is a double-blind, placebo controlled study to assess the safety and efficacy of BI1015550 on patients with IPF. It is a phase 3 study and will including physical exams, a CT, questionnaires, safety lab samples, lung function testing, and ECGs.
A double-blind randomized placebo-controlled study to assess the safety and efficacy of nebulized PC945 when added to systemic antifungal therapy for the treatment of refractory invasive pulmonary aspergillosis
This Phase 3, double-blind, randomized, placebo-controlled, parallel-group, multi-center, international study will assess the efficacy, safety and tolerability of nebulized PC945 when added to systemic antifungal therapy for the treatment of refractory invasive pulmonary aspergillosis (IPA).
A5394: Safety Tolerability and Impact of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants with Both Chronic Hepatitis B and HIV
A5394 is a phase II, randomized, double-blind, placebo-controlled clinical trial to assess the safety, tolerability, and efficacy of 24 weeks of treatment with Selgantolimod (SLGN). Intensive PK sampling will be conducted in the first 12 participants who enroll into the study.
Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome (AEGIS-II)
This is a multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse CV events (MACE) in subjects with Acute Coronary Syndrome (diagnosed with STEMI or NSTEMI), who are receiving evidence-based medical therapy.
A Randomized Double-Blind Double-Dummy Active-Controlled Study Comparing the Efficacy Safety and Tolerability of ABBV-951 to Oral Carbidopa/Levodopa in Advanced Parkinson's Disease Patients
Please see Section 1 of the attached protocol.
A Phase 3 Randomized Double-Blind Placebo-Controlled Parallel Arm Multicenter Study Evaluating the Efficacy and Safety of Pridopidine in Patients with Early Stage of Huntington Disease
PROOF-HD is a placebo-controlled (double blind) multicenter Phase 3 trial of Pridopidine in Huntington Disease patients. Recruitment: 480 participants at 60 sites, a target of 8 participants per site. Procedures include administration of study drug or placebo in tablet form twice daily for a period of 67-80 weeks with option …
Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia: A Multicenter Randomized Double blind Placebo controlled Study with a Long-term Open-label Extension
Efficacy of nipocalimab in patients with warm autoimmune hemolytic anemia (wAIHA) Durable response in improvement in hemoglobin (Hgb), defined as attainment of the following at 3 consecutive visits, where at least the first is at or before Week 16, without the need of rescue therapy: 1- Hgb concentration greater than …
I5T-MC-AACI Assessment of Safety Tolerability and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease Phase II
This protocol is an 18-month, multicenter, randomized, double-blind, placebo-controlled, phase 2 study comparing 1400 mg of donanemab versus placebo over 76 weeks in approximately 500 patients with early symptomatic AD. Study duration including screening and post treatment is up to 133 weeks. Study drug will be prepared and stored at …
A randomized double-blind placebo controlled 3-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjogren's syndrome (NEPTUNUS-2)
This is a 52 wk, randomized, double-blind study to demonstarte the clinical efficacy, safety, and tolerability of ianalumab compared to placebo in patients with active Sjogren's syndrome. Pts will receive a subcutaneous injection of ianalumab/placebo monthly, in addition to salivary flow assessments, blood and urine sampling, PROs, and optional assessments …
A multi-center double-blind placebo-controlled Phase 4 study in patients with pulmonary arterial hypertension to assess the effect of selexipag on daily life physical activity and patients self-reported symptoms and their impacts
This is a prospective, multi-center, double-blind, randomized, placebo-controlled, parallel-group, exploratory Phase 4 study. The purpose is to identify the effect of selexipag on daily life physical activity assessed by a wearable device in patients with PAH (WHO Group 1). Approximately 100 patients will be enrolled in the study at 45 …
Please choose between Voice or SMS based delivery of verification code
or